VIM and breast cancer: OC treatment increased the tumor expression of epithelial markers (E-cadherin) while decreasing the expression of mesenchymal markers (vimentin), as well as decreasing the activation of Met and HER2 receptors and the serum levels of CA 15-3 human breast cancer marker [157].